BCM
APLS

Burrage Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Burrage Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-80,727
Closed -$3.46M – 23
2021
Q1 		$3.46M Sell
80,727
-630
-0.8% -$29.8K 2.81% 17
2020
Q4 		$4.65M Buy
81,357
+4,553
+6% +$193K 3.55% 12
2020
Q3 		$2.32M Buy
76,804
+2,352
+3% +$70.3K 1.83% 20
2020
Q2 		$2.43M Hold
74,452
– – 1.7% 22
2020
Q1 		$2.04M Sell
74,452
-775
-1% -$27.5K 2.01% 21
2019
Q4 		$2.3M Buy
+75,227
New +$2.08M 1.54% 20

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Burrage Capital Management's APLS Position: Q2 2021 in Review

Burrage Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2021, closing a stake of 80,727 shares — an estimated $3.46M sold.

Burrage Capital Management first reported a position in APLS in Q4 2019 and held it in 6 quarters. The position peaked at $4.65M in Q4 2020. 204 funds tracked by Wall St. Rank hold APLS as of Q2 2021.

  • Burrage Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Burrage Capital Management sold 80,727 Apellis Pharmaceuticals shares in Q2 2021, an estimated $3.46M.
  • Burrage Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2019 and held it in 6 quarters.
  • Burrage Capital Management's Apellis Pharmaceuticals position peaked at $4.65M in Q4 2020.
  • 204 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2021.

Based on Burrage Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.